Oak Therapeutics and KU Medical Center cooperate on NIH-funded research
Together with Kansas University Medical Center, Oak Therapeutics will contribute to improving infant antiretroviral therapy (ART). One of...
Oak Therapeutics cooperates with KU Medical Center on HIV solutions
Oak Therapeutics and the Department of Family Medicine at the University of Kansas Medical (KUMC) Center will cooperate on the...
Oak Therapeutics receives NIH/NIAID contract
We are proud to announce that we have received a contract from NIAID, the National Institute of Allergy and Infectious Diseases, a...
Oak Therapeutics in line for SBIR award
We are proud to report that we are in the final stages of negotiating an SBIR award with the National Institute for Allergens and...
Oak Therapeutics receives Central Coast Innovation Award!
On Friday, February 26th, the Pacific Coast Business Times announced the winners of the 2016 Central Coast Innovation Awards. We're proud...
Listen to our co-founder Ed Maliski
Ed Maliski, Ph.D. recently was interviewed by entrepreneur Mark Sylvester for the 805 Conversations podcast. Among other topics, Ed...
The beginning of a vaccine - the end of malaria?
Yesterday, a much-anticipated announcement was made on a variety of media outlets – European regulators approved Mosquirix, the...
Oak Therapeutics Flip Book online
We've had a pretty neat folder that describes what Oak Therapeutics is about for quite a while. This folder is now also online as a flip...
The Pacific Coast Business Times reports on us!
In it's July 3-9 edition, the Pacific Cost Business Times reported on the pre-clinical study that we just completed on our malaria...
It's all about the children - video
We just released our new video on our contribution to solving the malaria problem. Our gratitude goes to Dariush Apfelthaler (vide0) as...
